BioNTech Counts on a Wave of Cancer Data to Offset Shrinking COVID Sales and a Changing Guard

BioNTech closed at €80.20, down 4.86% weekly, as COVID revenue declines and net loss widens. However, an expanding oncology pipeline with 25+ trials and €10B cash keep analysts bullish; average target €107.

BioNTech closed Friday at €80.20, down 1.41% on the day and 4.86% for the week. Over the past month, however, the shares have gained 7.36% as the company tries to rewrite its growth story in real time. The stock remains 24.2% below its January high of €105.80 and 17.66% lower than a year ago — a reminder that the road from pandemic darling to oncology powerhouse is proving longer and choppier than many hoped.

First?quarter 2026 results laid bare the challenge. Revenue contracted sharply compared with the prior?year period as COVID?19 vaccine sales continued to normalise. The net loss widened, driven by higher research spending on the lead oncology candidates Pumitamig and Gotistobart, plus integration costs associated with the 2025 acquisitions of BioNTech China and CureVac. To conserve cash and streamline operations, the company is closing its manufacturing sites in Idar?Oberstein, Marburg and Tübingen by the end of 2027, with the Singapore plant following in the first quarter of that year. Management is exploring sale options for each facility, including partial or full divestitures.

Yet the pipeline is expanding even as the factory footprint shrinks. CEO Ugur Sahin has described 2026 as a particularly data?rich year, and the numbers back him up: BioNTech now runs more than 25 phase?2 and phase?3 studies, including 13 pivotal trials. Seven late?stage data readouts are still pending. The pan?tumour programme Pumitamig has already delivered encouraging signals from the global ROSETTA?Lung?02 study in non?small?cell lung cancer, while Gotistobart showed promising overall?survival data in platinum?resistant ovarian cancer as a potential chemotherapy?free option. Five new registrational studies have been initiated on the back of these results.

That pipeline breadth is the bull case. Backed by roughly €10 billion in cash — or €16.7 billion when including securities — the company can fund its oncology build?out and a share buyback programme of up to US$1 billion without needing to raise fresh equity. The Wall Street consensus still leans bullish, with 15 buy ratings versus just five holds, and the average price target stands at €107.05, well above Friday’s close. Analysts argue that if the data keep coming through, the market will gradually reprice the stock for a post?COVID reality.

The bear case, however, is about execution and timing. The gap between early?stage promise and approved, commercialised drugs is wide, and high R&D spending continues to eat into operating cash. Any clinical delay would put additional pressure on the balance sheet. Adding to the uncertainty, the company has confirmed a leadership transition: the founders are preparing to step back from day?to?day management. A change at the top could disrupt strategic continuity just as the oncology pivot reaches its most critical juncture.

Technically, the stock sits in a neutral zone. The relative strength index is at 48.5, and the price is 5.79% below its 200?day moving average of €85.13. The next clear catalyst is the second?quarter earnings call on 4 August, where investors will look for updates on study timelines, R&D spending and the succession plan. Until then, the direction will be set by whatever data points emerge from the clinical pipeline.

If the upcoming readouts — especially from the Pumitamig and Gotistobart programmes — confirm the early signals and show a clean safety profile, a recovery toward the 100?day average of €81.78 and eventually the consensus target is plausible. Disappointment, on the other hand, could send the shares back toward the 50?day average of €79.38 or even the 52?week low of €68.35. With no single make?or?break event on the calendar, BioNTech’s summer will be decided by the slow accumulation of clinical evidence — and the market’s patience for a transformation that is still very much a work in progress.